Consistent with findings from larger-scale studies [38,40], we report more favorable outcomes for the HER2-low subset of breast cancer patients, possibly due to a higher frequency of ER-positive tumors among this group, although previous data suggest that the clinical benefit of ADC molecules for HER2-low patients is independent of ER status [13,39]. This evidence concerns the gene ESR1 and breast cancer.